Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Similar articles for PubMed (Select 17784815)

1.

Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.

Files JG, Hargrove D, Delute L, Cantillon M.

J Interferon Cytokine Res. 2007 Aug;27(8):637-42.

PMID:
17784815
2.

Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.

Monzani F, Meucci G, Caraccio N, Saviozzi M, Casolaro A, Moscato G, Lombardo F, Mosti S, Scagnolari C, Bruschi F, Antonelli G, Ferrannini E, Murri L.

J Interferon Cytokine Res. 2002 Jul;22(7):773-81.

PMID:
12184915
3.

Neutralizing antibodies to interferon.

Noronha A.

Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22. Review.

PMID:
17562846
4.

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.

Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.

J Immunol Methods. 2007 Apr 10;321(1-2):19-31. Epub 2007 Feb 20.

PMID:
17335844
5.

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.

Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G.

J Neurol. 2007 May;254(5):597-604. Epub 2007 Apr 10.

PMID:
17420930
6.
7.

Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.

Fernández O, Mayorga C, Luque G, Guerrero M, Guerrero R, Leyva L, León A, Blanca M.

J Neurol. 2001 May;248(5):383-8.

PMID:
11437159
8.

Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC.

Arch Neurol. 2010 Sep;67(9):1095-101. doi: 10.1001/archneurol.2010.218.

PMID:
20837854
9.

Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies.

Prümmer O, Streichan U, Heimpel H, Porzsolt F.

J Immunol Methods. 1994 May 2;171(1):45-53.

PMID:
8176238
10.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group.

Clin Ther. 2007 Jun;29(6):1128-45.

PMID:
17692727
11.

Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?

Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.

Mult Scler. 2008 Jul;14(6):837-42. doi: 10.1177/1352458508088942. Epub 2008 May 27.

PMID:
18505772
12.

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE.

J Interferon Cytokine Res. 1998 Dec;18(12):1025-30.

PMID:
9877445
13.

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.

Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19.

PMID:
19299439
14.

Optimising MS disease-modifying therapies: antibodies in perspective.

Giovannoni G.

J Neurol. 2004 Sep;251 Suppl 5:v30-v35. Review.

PMID:
15549353
15.

Epitope specificity of neutralizing antibodies against IFN-beta.

Gneiss C, Reindl M, Berger T, Lutterotti A, Ehling R, Egg R, Deisenhammer F.

J Interferon Cytokine Res. 2004 May;24(5):283-90.

PMID:
15153311
16.

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.

Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R.

Immunopharmacology. 2000 Jul 20;48(2):95-100.

PMID:
10936507
17.

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T.

J Interferon Cytokine Res. 2001 Mar;21(3):167-71.

PMID:
11331039
18.

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group.

Neurology. 2005 Jul 12;65(1):33-9. Epub 2005 May 11.

PMID:
15888603
19.
20.

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy.

Hesse D, Sørensen PS.

Eur J Neurol. 2007 Aug;14(8):850-9. Review.

PMID:
17662004
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk